Real-world evidence on PET use in Hodgkin lymphoma: An Argentinian perspective

Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL

PET scanning in patients with classical Hodgkin lymphoma outside of Europe and North America

Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma

Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors

Significance of gut microbiota in patients receiving CAR T cell immunotherapy

INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma

Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients

Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL

Integrated genomic analysis identifies UBTF tandem duplications as a subtype-defining lesion in paediatric AML

Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase

Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first remission after intensive chemo

Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL

Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML

Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups

Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma

EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs

Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM

Latest in combination therapy for NDMM patients

Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma.

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients

Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma

Study indicates circulating tumour cell assessment should be part of multiple myeloma diagnostic workup

Initial treatment options for relapsed/refractory multiple myeloma patients

ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iNHL

Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL